Immuneering Appoints Leah R. Neufeld as Chief People Officer
October 20 2022 - 6:50AM
Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company
that aims to create medicines for all patients with solid tumors
driven by RAS mutations and other MAPK pathway activation events,
today announced the appointment of Leah R. Neufeld to the newly
created position of Chief People Officer, effective immediately.
“Our world-class team of Immuneers enables us to accomplish
great things, and in Leah we now have a Chief People Officer worthy
of our people,” stated Ben Zeskind, Ph.D., Co-Founder and Chief
Executive Officer of Immuneering. “Leah is a seasoned human
resources leader with decades of experience in the life sciences
industry. We welcome her and look forward to leveraging her
expertise to continue making Immuneering a great place for every
Immuneer to work and to grow, and to help add additional top talent
to our team.”
"Immuneering is a dynamic company utilizing a proprietary,
novel, translational bioinformatics platform approach to drug
development and I look forward to supporting the company's growth
during this critical time, as we transition from preclinical
development into human clinical trials," noted Ms. Neufeld.
Ms. Neufeld joins Immuneering from Luzsana Biotechnology, where,
since August 2021, she served as Chief Human Resources Officer, and
as part of the executive team, helped establish Luzsana globally as
a subsidiary of Hengrui Medicines, the largest Pharma company in
China. Previously, she was the Vice President, People, at Prevail
Therapeutics, from 2019 and following its acquisition by Eli Lilly
in 2021. Prior to that, from 2015 through 2019, Ms. Neufeld was the
Head of Human Resources at Intercept Pharmaceuticals. Before that,
she was the Global Head of Human Resources for NPS Pharma until it
was acquired by Shire Pharmaceuticals in 2015. From 2009 to 2014,
she held positions of increasing responsibility at Daiichi Sankyo
Pharma Development, most recently serving as Director of Human
Resources. Earlier in her career, from 2002 to 2009, she held
various human resources positions at Johnson & Johnson,
including Manager of Human Resources in the consumer division and
its oncology company called Ortho Biotech.
Ms. Neufeld earned a B.A. in psychology from the American
University and an M.S. in career counseling and organization
development from Johns Hopkins University.
About Immuneering
Corporation Immuneering
aims to create medicines for all patients with solid tumors
driven by RAS mutations and other MAPK pathway activation
events. Immuneering has more than a decade of experience
applying translational bioinformatics to generate insights into
drug mechanism of action and patient treatment response. Building
on this experience, Immuneering's disease-agnostic
discovery platform enables the company to create product
candidates based on 1) biological insights that are both
counterintuitive and deeply rooted in data, and 2) novel
chemistry. Immuneering's lead product candidate,
IMM-1-104, aims to achieve pan-RAS activity that selectively
impacts cancer cells to a greater extent than healthy cells.
IMM-1-104 is designed to be a highly selective third generation
dual MEK inhibitor that modulates the signaling dynamics of the
MAPK pathway by driving deep cyclic inhibition that deprives tumor
cells of the sustained proliferative signaling required for rapid
growth, while providing a cadenced, normalized level of signaling
designed to spare healthy cells. IMM-1-104 is being developed to
treat advanced solid tumors in patients harboring RAS mutations,
and is translationally guided
by Immuneering's proprietary, human-aligned 3D tumor
modeling platform combined with patient-aligned bioinformatics. In
addition to the Phase 1 ready IMM-1-104 drug
program, Immuneering is currently
evaluating IMM-6-415 in IND-enabling studies. The earlier
Immuneering drug discovery pipeline includes five additional
oncology programs as well as two neuroscience programs.
Forward-Looking StatementsThis press release
includes certain disclosures that contain "forward-looking
statements," including, without limitation, statements regarding
Immuneering’s expectations regarding the treatment potential of
IMM-1-104 and IMM-6-415, the timing of commencement and enrollment
of the Phase 1/2a clinical trial for IMM-1-104, the design,
enrollment criteria and conduct of the Phase 1/2a clinical trial,
the timing of submission of the IND and commencement of clinical
trials for IMM-6-415 and Immuneering’s ability to advance its
pipeline and further diversify its portfolio and make progress
towards its longstanding goal of creating better medicines for
cancer patients. Forward-looking statements are based on
Immuneering’s current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict.
Factors that could cause actual results to differ include, but are
not limited to, the risks inherent in oncology and neuroscience
drug development, including target discovery, target validation,
lead compound identification, lead compound optimization,
preclinical studies and clinical trials. These and other risks and
uncertainties are described more fully in the section titled "Risk
Factors" in Immuneering’s most recent Form 10-Q filed with the U.S.
Securities and Exchange Commission. Forward-looking statements
contained in this announcement are made as of this date, and
Immuneering undertakes no duty to update such information
except as required under applicable law.
Corporate Contact:Rebecca Kusko,
Ph.D.Immuneering Corporation617-500-8080rkusko@immuneering.com
Investor Contact:Susan A. NoonanS.A. Noonan
Communications917-513-5303susan@sanoonan.com
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jul 2023 to Jul 2024